Our vision

Oxcia AB vision is to transform state-of-art science into valuable drugs and health products to improve lives.

Organisation


Chairman of the Board
ulrika.warpmanberglund@oxcia.se


CEO, Member of the Board
jan.zetterberg@oxcia.se
Thomas Helleday
CSO, Member of the Board
thomas.helleday@oxcia.se
Jan Benjaminson
Member of the Board
jan.benjaminson@oxcia.se

Head of administration and accounting
hakan.nordlander@oxcia.se

Project Leader of Libragel
eva.bjorkstrand@oxcia.se

Head of Clinical Development
teresa.sandvall@oxcia.se

Head marketing and communication
hanna.martinsson@oxcia.se

Head of Intellectual property
kerstin.genetay@oxcia.se 

CMC Director
martin.scobie@oxcia.se
 
 

Get to know us


Chairman of the Board
ulrika.warpmanberglund@oxcia.se

Ulrika Warpman Berglund is a Pharmacist and has a PhD in Pharmacology. She joined Pharmacia in 1997, where she worked as a scientist, section head and project leader. In 2000 she joined Biovitrum as project leader as well as group leader.

In 2009, Ulrika left Sweden to join Prosidion Ltd in Oxford, UK, where she successfully established a pharmacology department and was part of the Research steering group. Ulrika has proven strong leader qualities and drug discovery know how in a number of multi-disciplinary project teams, pharmacology teams, steering teams and during restructuring processes and thereby gained confidence in her ability of strategic thinking, as well as her ability to set up visions, organise and establish new teams, communicate, and collaborate. She has directed business goals and together with her teams significantly contributed towards achieving them. Ulrika has successfully managed research projects leading to outlicensing of projects and developing of clinical candidates. In 2012, she joined Professor Helleday at Karolinska Institute to perform drug discovery in an academic setting.


CEO, Member of the Board
jan.zetterberg@oxcia.se

thoJan Zetterberg finished law studies in 1975 after which he worked for the Swedish Court system until 1979. He joined AstraZeneca (Astra) in 1983 where he held several roles such as Legal Counsel, Senior Counsel, Vice President, Strategy, Intellectual Property and since 1999 as Assistant General Counsel.

Jan Zetterberg provided global legal support in all areas of business including corporate functions, R&D, Operations, and Business Development. In addition he was appointed line manager for AstraZeneca Trademarks group in 2008. Jan Zetterberg retired from AstraZeneca end 2011. He started Zedur AB in January 2012 to provide consultancy services in the legal and compliance area supporting primarily small to medium size Life Science industry. He became Partner and Chairman of the Board of Zelibra AB in January 2012. Zelibra AB is a Swedish company offering the services of internationally experienced consultants to the life science industry. Its mission is to help bring life science innovations to the right market in a timely and cost-effective manner. In January 2014 Jan Zetterberg was elected Chairman of the Board of ExThera AB.


Member of the Board
thomas.helleday@oxcia.se

Thomas Helleday is Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, where he heads a large multidisciplinary translational research group focusing on understanding DNA damage response biology and translating the findings into novel anti-cancer treatments concepts and drugs.  The group was first to demonstrate the synthetic lethality concept for treating cancer by showing homologous recombination defective cancers (e.g., BRCA) were sensitive to PARP inhibitors. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) and ERC advanced grants (2010 and 2016).

Prof Helleday is a honorary professor at University of Sheffield where he previously were Cancer Centre Director and has previous professorial chairs at University of Oxford and Stockholm University

Eva Sjökvist Saers is a Pharmacist and has a PhD from the Faculty of Pharmacy, University of Uppsala. Eva joined the Astra group (Astra Pain Control and AstraZeneca) as Director within pharmaceutical research and development, with responsibility of e.g. product development, manufacturing to clinical trials and tech transfer to large scale manufacturing. For more than 15 years Eva was the head and CEO of APL (Apotek Produktion & Laboratorier AB), a pharmaceutical company with more than 500 employess and a revenue of SEK 1,4 billion. APL has the commission from the state to develop and manufacture pharmaceuticals for patients with special needs. APL is also a CDMO (Contract Development and Manufacturing Organisation) that supports life science companies with drug development and manufacturing services.  Eva is today active in boards in life science as a board member in e.g. Recipharm AB, IDL Biotech AB and Bluefish Pharmaceuticals AB. Eva is the chairman of Swelife, a strategic innovation program appointed by the government. She is the former chairman of the Swedish Society of Pharmaceutical Sciences (Apotekarsocieteten), former vice chairman of SwedenBIO, the national association of the life science industry, and former boardmember of KIHAB (Karolinska Institutet Holding AB).

Jan Benjaminson
Member of the Board
jan.benjaminson@oxcia.se

Jan Benjaminson has a MSc in Business and economics from Lund University. He has long standing experience from IPO, financing and capital raising as member of the board, CEO and CFO from various listed and unlisted software companies in Sweden. Jan specialties during the last twenty years are more and more concentrating on business development, building up organizations, focusing operations, turnarounds, seeking capital to expansions and IPOs (Initial Public Offerings). Jan has published more than 50 quarterly report to the financial market from company listed and traded in Sweden and have been involved in 12-15 funding’s, capital raise, financing’s and IPO’s.The first twelve year after his degree from University of Lund he was working in traditional industries. From year 2000 he has focused on SME and mainly in tech companies. By today he has a full-time employment as CFO in an esports company, G-Loot Global Esport and besides Oxcia assignment, additional three board assignments; Mid cap listed Starbreeze and two private owned gaming companies.


Project Leader of Libragel
eva.bjorkstrand@oxcia.se

Eva Björkstrand is a Pharmacologist and has a PhD in pharmacology from Karolinska Institutet. She has more than 20 years of experience from pharmaceutical industry (e.g. Pharmacia, Biovitrum and Orexo), where she worked as a scientist, section head, project leader and sustainability manager.

During the last years at Orexo, she worked in the quality management department, responsible for building a document handling system in addition to her role as sustainability manager. During her years in pharma industry Eva has gained experience in all areas – from early drug discovery to manufacturing of drugs including quality management. In February 2020 she joined Oxcia as a project manager for the medical device Libragel. Eva has successfully managed many types of projects, from research- to restructuring projects. As a project manager Eva has proven to be result-focused, self-motivated and she really likes challenges.  


Head of administration and accounting
hakan.nordlander@oxcia.se

Håkan Nordlander have 38 years of work experience, including work in Audit Company and a position as CFO but mainly 30 years of employment in AstraZeneca in different positions in the financial area.

My main expertise is in the areas of accounting, budgeting and financial reporting but I have also experience from Mergers & acquisitions and I have also over a long period of time been responsible for a number of global deals from a finance perspective. The global deals has been In and out licensing deals as well as Co- promotion and Global Alliances deals.


Head of Clinical Development
teresa.sandvall@oxcia.se

Teresa Sandvall a clinical trials specialist with 16 years of experience from the pharmaceutical industry (i.e. Biovitrum and Novartis) as well as working at Karolinska University Hospital as a start up- specialist regarding clinical trials and with the Swedish CardioPulmonary bioImage Study (SCAPIS).

That is a world unique project in the field of heart, blood vessels and lungs in collaboration with academia and the Swedish Heart and Lung Foundation. She has experience from all aspects of clinical trials from small studies to large multi-centre studies, from Phase 1 to phase 3, and provides knowledge on regulatory requirements and strategies, guidelines, protocol assistance, planning, initiating, executing and finalizing clinical trials. Teresa has also been working as a research scientist in preclinical projects with drug design to find new drug candidates and involved in driving projects from early to late preclinical phase.


Head of Intellectual property
kerstin.genetay@oxcia.se

Kerstin Genetay has worked more than 20 years as coordinator of development & IP projects in the pharmaceutical industry, both in Big Pharma (Pharmacia & Pfizer) and smaller Biotech.

She has major experience of Project Portfolio Management with particular emphasis on prioritization of projects and subsequent patent portfolio management. Kerstin is a Swedish representative in ISO, relating to Medical Devices Technology and has managed projects of device – pharmaceutical compatibility & medical device related intellectual property issues. Kerstin has Dr Med Sc in molecular genetics & bacteriology from the Karolinska Institute.


CMC Director
martin.scobie@oxcia.se

Martin Scobie received a PhD in chemistry from the University of Edinburgh. After post-doctoral studies at the Universities of Geneva, Bath and Strathclyde, he was one of the first scientists recruited by the start-up company Oxford Diversity PLC where he worked as project leader from 1995-2000, gaining commercial and project management experience on a number of successful programs.

In 2000 he moved to Uppsala in Sweden where he worked first with Pharmacia AB, then Biovitrum AB in medicinal chemistry team leader roles. In 2010 he was recruited by Prof. Thomas Helleday to build-up a medicinal chemistry team in the Helleday Lab. The team is based at Karolinska Institutet and is focused on developing inhibitors to novel targets involved in DNA repair and metabolism. Since 2013 Martin has been closely involved in CMC and pharmaceutical development of Karonudib (Oxcia’s MTH1 inhibitor which is currently in clinical trials), and in the discovery of several other small molecule inhibitors in Oxcia’s pipeline.


Head marketing and communication
hanna.martinsson@oxcia.se

Hanna has a background in sales and business development from several different companies. Her special interest is in digital marketing. She has previous experiences as account manager and has very successfully established custom related services and tailored events, campaigns and product placements.